刘务玲,姚尧,陈娟,吴昌学,宋晶睿,王春林,邱剑飞,王立平,朱伟明,龙群,李艳梅
LIU Wuling,YAO Yao,CHEN Juan,WU Changxue,SONG Jingrui,WANG Chunlin,QIU Jianfei,WANG Liping,ZHU Weiming,LONG Qun,LI Yanmei

• 1:贵州省中国科学院天然产物化学重点实验室
• 2:贵州医科大学
• 3:中国海洋大学

摘要(Abstract)：

目的:研究双吲哚马来酰亚胺衍生物GZWM-051(简称化合物GZWM-051)对人白血病HEL细胞周期及分化的影响。方法:HEL细胞分为对照组(DMSO处理)和化合物GZWM-051组(0.025、0.050、0.100μmol/L化合物GZWM-051处理,分别为低剂量、中剂量、高剂量组),采用流式细胞术检测细胞周期及分化水平,采用Western blot法检测细胞Cyclin B1、c-Myc、STAT3及P-STAT3蛋白表达水平。结果:处理24 h后,与对照组HEL细胞相比,化合物GZWM-051中、高剂量组HEL细胞处于G1和S期细胞数量显著减少,处于G2期的数量显著增加,差异有高度统计学意义(P<0.01);相比对照组,作用48 h后化合物GZWM-051低、中、高剂量组HEL细胞的CD41a和CD71均上调;与对照组HEL细胞对比,中剂量及高剂量化合物GZWM-051组HEL细胞生长相关蛋白c-Myc表达水平降低,差异有统计学意义(P<0.05或P<0.01);与对照组HEL细胞对比,低、中及高剂量的化合物GZWM-051组HEL细胞的P-STAT3表达水平降低(P<0.05或P<0.01),中、高剂量化合物GZWM-051组HEL细胞周期蛋白Cyclin B1表达水平降低(P<0.05)。结论:化合物GZWM-051不仅能诱导白血病HEL细胞发生G2周期阻滞,促进其向巨核及红系进行分化,抑制细胞恶性增殖,还能失活STAT3关键通路。
Objective: To study the effect of bisindolylmaleimide derivative GZWM-051(abbreviated as compound GZWM-051) on cell cycle and differentiation of human leukemia HEL cells. Methods: HEL cells were divided into control group(DMSO treatment) and treatment groups(low dose 0.025, medium dose 0.050, high dose 0.100 μmol/L compound GZWM-051). Cell cycle and differentiation were assayed using flow cytometry, The expression levels of Cyclin B1, c-Myc, STAT3 and P-STAT3 were detected by Western blot. Results: After treatment for 24 h, compared with control group, the cell numbers in G1 and S phases were significantly decreased in medium and high dose groups, while the cell numbers in G2 phase were remarkably increased(P<0.01). At 48 h after the treatment, the expression levels of CD41 a and CD71 were upregulated relative to control group, while the expression levels of c-MYC and Cyclin B1 was downregulated in both medium and high dose treatment(P<0.05 or P<0.01, P<0.05). In addition, the treatment downregulated phosphorylation levels of STAT3(P<0.05 or P<0.01). Conclusion: Compound GZWM-051 can not only induce G2 cycle arrest and differentiation in leukemia HEL cells, but also inactivate STAT3.

关键词(KeyWords)： 白血病;双吲哚马来酰亚胺衍生物;分化;G2期阻滞;信号转导子和转录激活子3;人红白血病细胞系
leukemia;bisindolylmaleimide derivative;differentiation;G2 phase arrest;signal transducer and activator of transcription-3;human erythroleukemia cell line

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(81700169)

作者(Author): 刘务玲,姚尧,陈娟,吴昌学,宋晶睿,王春林,邱剑飞,王立平,朱伟明,龙群,李艳梅
LIU Wuling,YAO Yao,CHEN Juan,WU Changxue,SONG Jingrui,WANG Chunlin,QIU Jianfei,WANG Liping,ZHU Weiming,LONG Qun,LI Yanmei

DOI: 10.19367/j.cnki.1000-2707.2019.09.001

参考文献(References)：

• [1] ALLART-VORELLI P,PORRO B,BAGUET F,et al.Haematological cancer and quality of life:a systematic literature review [J].Blood Cancer Journal,2015,5(4):e305.
• [2] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2019 [J].CA:A Cancer Journal for Clinicians,2019,69(1):7-34.
• [3] ZHANG J,GU Y,CHEN B.Mechanisms of drug resistance in acute myeloid leukemia [J].Onco Targets and Therapy,2019,12:1937-1945.
• [4] XU W P,ZHANG X,XIE W F.Differentiation therapy for solid tumors [J].Journal of Digestive Diseases,2014,15(4):159-165.
• [5] LESZCZYNIECKA M,ROBERTS T,DENT P,et al.Differentiation therapy of human cancer:basic science and clinical applications[J].Pharmacology &Therapeutics,2001,90(2-3):105-156.
• [6] GHELLI R A,IACOBUCCI I,MARTINELLI G.The cell cycle checkpoint inhibitors in the treatment of leukemias [J].Journal of Hematology & Oncology,2017,10(1):77.
• [7] MARTIN P,PAPAYANNOPOULOU T.HEL cells:a new human erythroleukemia cell line with spontaneous and induced globin expression [J].Science,1982,216(4551):1233-1235.
• [8] 陈丽,杨珏,邱剑飞,等.Isogarcinol对人红白血病细胞HEL的抗肿瘤作用及机制 [J].贵州医科大学学报,2019,44(1):35-41;47.
• [9] 徐倩,赵亚玲,付建珠,等.AG490对HEL细胞VEGF和HIF-1α表达的影响 [J].中国病理生理杂志,2015,31(12):2158-2163.
• [10]WANG N,FAN Y,YUAN C M,et al.Selective ERK1/2 agonists isolated from Melia azedarach with potent anti-leukemic activity [J].BMC Cancer,2019,19(1):764.
• [11]LIU T,XIA L,YAO Y,et al.Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis [J].Cell Death & Disease,2019,10(2):117.
• [12]SAAD N S,ELNAKISH M T,BRUNDAGE E A,et al.Assessment of PKA and PKC inhibitors on force and kinetics of non-failing and failing human myocardium [J].Life Sciences,2018,215:119-127.
• [13]STRACHAN-WHALEY M R,REILLY K,DOBSON J,et al.Map kinase and PKC signaling pathways modulate NGF-mediated apoE transcription [J].Neuroscience Letters,2015,595:54-59.
• [14]MORCEAU F,CHATEAUVIEUX S,ORSINI M,et al.Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways [J].Biotechnology Advances,2015,33(6):785-797.
• [15]NOWAK D,STEWART D,KOEFFLER H P.Differentiation therapy of leukemia:3 decades of development [J].Blood,2009,113(16):3655-3665.
• [16]STUDZINSKI G P,HARRISON J S,WANG X,et al.Vitamin D control of hematopoietic cell differentiation and leukemia [J].Journal of Cellular Biochemistry,2015,116(8):1500-1512.
• [17]YAN M,LIU Q.Differentiation therapy:a promising strategy for cancer treatment [J].Chinese Journal of Cancer,2016,35:3.
• [18]DE T H.Differentiation therapy revisited [J].Nature Reviews Cancer,2018,18(2):117-127.
• [19]MILLS C C,KOLB E A,SAMPSON V B.Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy [J].Cancer Research,2018,78(2):320-325.
• [20]LIU Y,FAN D.Ginsenoside Rg5 induces G2/M phase arrest,apoptosis and autophagy via regulating ROS-mediated MAPK pathways against human gastric cancer [J].Biochemical Pharmacology,2019,168:285-304.
• [21]LU W J,PENG W,SUN Q Q,et al.A novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models [J].Cell Death Discovery,2018,4:24.
• [22]MA D,WANG P,FANG Q,et al.Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-alpha-mediated G2/M phase arrest in chronic myeloid leukaemia [J].Artificial Cells,Nanomedicine and Biotechnology,2018,46(SUP3):208-216.
• [23]SEIF F,KHOSHMIRSAFA M,AAZAMI H,et al.The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells [J].Cell Communication and Signaling,2017,15(1):23.
• [24]YU H,LEE H,HERRMANN A,et al.Revisiting STAT3 signalling in cancer:new and unexpected biological functions [J].Nature Reviews Cancer,2014,14(11):736-746.
• [25]YANG S,SI L,JIA Y,et al.Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis,G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways [J].Official Journal of the Balkan Union of Oncology,2019,24(3):975-981.
• [26]FATHI N,RASHIDI G,KHODADADI A,et al.STAT3 and apoptosis challenges in cancer [J].International Journal of Biological Macromolecules,2018,117:993-1001.
• [27]ILIOPOULOS D,HIRSCH H A,STRUHL K.An epigenetic switch involving NF-kappaB,Lin28,Let-7 MicroRNA,and IL6 links inflammation to cell transformation [J].Cell,2009,139(4):693-706.
• [28]DU L,SUBAUSTE M C,DESEVO C,et al.MiR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers [J].PloS One,2012,7(6):e39167.
• [29]MAROTTA L L,ALMENDRO V,MARUSYK A,et al.The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors [J].The Journal of Clinical Investigation,2011,121(7):2723-35.
• [30]SCHROEDER A,HERRMANN A,CHERRYHOLMES G,et al.Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling [J].Cancer Research,2014,74(4):1227-1237.
• [31]STRAUSS B,HARRISON A,COELHO P A,et al.Cyclin B1 is essential for mitosis in mouse embryos,and its nuclear export sets the time for mitosis [J].The Journal of Cell Biology,2018,217(1):179-193.
• [32]DINGAR D,KALKAT M,CHAN P K,et al.BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors [J].Journal of Proteomics,2015,118:95-111.
• [33]DELMORE J E,ISSA G C,LEMIEUX M E,et al.BET bromodomain inhibition as a therapeutic strategy to target c-Myc [J].Cell,2011,146(6):904-917.

文章评论(Comment)：